Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-30

Study Completion Date

2030-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

NCT05461430

Pleural Effusion, Malignant Ascites, Malignant Carcinoma +29 more

RECRUITING

Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy

NCT00898430

Head and Neck Cancer

TERMINATED

Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study

NCT03707574

Advanced Malignant Neoplasm Advanced Melanoma Advanced Renal Cell Carcinoma +51 more

ACTIVE_NOT_RECRUITING

Biomarkers in Patients With Advanced Rhabdomyosarcoma

NCT01668095

Adult Rhabdomyosarcoma Childhood Alveolar Rhabdomyosarcoma Childhood Embryonal Rhabdomyosarcoma +5 more

COMPLETED

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

NCT05697198

Lung Cancer Ovarian Cancer Uterine Cancer +10 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stage III Breast Cancer Stage IV Breast Cancer Stage III Lung Cancer Stage IV Lung Cancer AML Multiple Myeloma in Relapse Carcinoma Carcinoma, Pancreatic Carcinoma of Lung Carcinoma, Non-Small-Cell Lung Carcinoma Breast Carcinoma Prostate Carcinoma, Hepatocellular Carcinoma, Renal Cell Carcinoma, Neuroendocrine Carcinoma, Small Cell Lung Carcinoma, Ovarian Carcinoma Bladder Carcinoma of Esophagus Carcinoma Cervix Carcinoma, Thymic Carcinoma, Ductal Carcinoma of the Head and Neck Carcinoma of the Lip Carcinoma of the Oral Cavity Carcinoma of Unknown Primary Carcinoma of the Skin Carcinoma of the Anus Carcinoma of the Larynx Carcinoma of the Penis Carcinoma of the Oropharynx Carcinoma of the Appendix Carcinoma of the Paranasal Sinus Carcinoma of the Vulva Malignant Pleural Effusion Malignant Ascites Mesothelioma Cholangiocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Carcinoma-Associated Malignant Fluid

Diagnosis of any kind of carcinoma with a malignant fluid (pleural effusion or ascites) where drainage is clinically indicated as part of SOC, and a new course of treatment is upcoming.